University of Vermont Medical Center
This study is a single arm, non-randomized feasibility study with tolerability and toxicity evaluation as primary endpoints which seeks to determine if a modified administration schedule of capecitabine with oxaliplatin will result in less toxicity than standard FOLFOX or CAPOX regimens.
Inclusion Criteria: * Patient with GI malignancy * Provider plans non-curative intent treatment with either CAPOX or FOLFOX (mFOLFOX6) at standard dosages for \>3 months NOTE: Patient is not required to have radiologically measurable disease. NOTE: Planned administration of other anti-cancer medications (eg bevacizumab, epidermal growth factor receptor antibodies, immunotherapy, tyrosine kinase inhibitors) is allowed. Exclusion Criteria: * Patients not meeting standard hematologic parameters for chemotherapy administration as follows: * Absolute neutrophil count (ANC) ≥ 1500 * Platelet…
85 mg/m2 oxaliplatin
oral fluoropyrimidine 1000mg/m2
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.